SCHEMBL23600441

SCHEMBL23600441

CC(C)N1C(=O)N/C(=C\c2c[nH]c3ncccc23)C1=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
CHEK1 O14757 3/20 0.49
HASPIN Q8TF76 4/20 0.45
CCNT1 O60563 2/20 0.45
CDK9 P50750 2/20 0.45
CHEK2 O96017 1/20 0.40
CDK1 P06493 1/20 0.40
SRC P12931 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
GPR84 Q9NQS5 1/20 0.40
CDC7 O00311 5/20 0.40
MAP2K1 Q02750 1/20 0.38
AXL P30530 1/20 0.38
PIM1 P11309 2/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
MYC P01106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23600362 0.84 KMT2A (0.54) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL23600440 0.81 KMT2A (0.50) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL23600261 0.81 MYC (0.41) KMT2APIM1MYC
SCHEMBL29764664 0.81 MYC (0.41) KMT2APIM1MYC
SCHEMBL23582777 0.80 KMT2A (0.49) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL23600226 0.79 ALDH1A1 (0.56) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL1713841 0.79 KMT2A (0.48) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL1713843 0.79 KMT2A (0.48) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL23600351 0.79 HASPIN (0.50) KMT2ACHEK1HASPINCCNT1CDK9
SCHEMBL23600256 0.79 PIM1 (0.37) KMT2AHASPINCCNT1CDK9PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945569-A Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same 延世大学校产学协力团 2022-08-26 CN claimed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
EP-4083037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME Yonsei University, University-Industry Foundation(UIF). (KR) 2022-11-02 EP disclosed
WO-2021133037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME 연세대학교 산학협력단 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP KMT2A 3977/4885CHEK1 3461/4885HASPIN 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.